Login to Your Account



Clinic Roundup


Friday, September 30, 2011
Otonomy Inc., of San Diego, presented positive data from a Phase Ib study of OTO-104, its lead candidate, in patients with Meniere's disease. The data suggested patients treated with OTO-104 experienced clinically meaningful reductions in vertigo frequency and improvements in tinnitus compared to placebo.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription